Virbac SA (EPA:VIRP)
France · Delayed Price · Currency is EUR | Market Cap | 2.55B -4.5% |
| Revenue (ttm) | 1.49B +4.3% |
| Net Income | 155.85M +17.2% |
| EPS | n/a |
| Shares Out | 8.38M |
| PE Ratio | 16.37 |
| Forward PE | 14.24 |
| Dividend | 1.45 (0.48%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 6,681 |
| Open | 307.00 |
| Previous Close | 307.50 |
| Day's Range | 304.50 - 311.00 |
| 52-Week Range | 297.00 - 389.50 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 412.75 (+35.55%) |
| Earnings Date | Sep 17, 2026 |
About Virbac
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph... [Read more]
Financial Performance
In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for VIRP stock is "Strong Buy." The 12-month stock price target is €412.75, which is an increase of 35.55% from the latest price.
News
Virbac Earnings Call Transcript: H1 2026
H1 2026 saw 7.4% revenue growth and an 18.8% EBIT margin, driven by strong Supercharge platforms and successful integration of acquisitions. Guidance for 2026 targets the upper end of sales growth and a 17% EBIT margin, with continued investment in R&D and capacity.
Virbac Earnings release: H1 2026
Virbac released its H1 2026 earnings on September 18, 2026, summarizing the period's financial results.
Virbac Quarterly report: H1 2026
Virbac has published its H1 2026 quarterly earnings report on September 18, 2026.
Virbac Slides: H1 2026
Virbac has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 18, 2026.
Virbac confirms outlook as Supercharge platforms drive profit growth
French animal health company Virbac reported higher half-year core profit on Thursday with a recurring operating profit, excluding amortization of assets due to acquisitions, rising 6.8% to 144.2 m...
Virbac Earnings release: Q2 2026
Virbac released its Q2 2026 earnings on July 20, 2026, summarizing the period's financial results.
Virbac : Declaration of the number of shares and voting rights 05/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac : Declaration of the number of shares and voting rights 04/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac : Public release of Virbac Annual Report at 31 December 2025.
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format.
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025 +2.2% at actual rates impacted by significant currency headwinds Balanced growth in both segments...
Virbac Earnings release: Q1 2026
Virbac released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.
Virbac : Declaration of the number of shares and voting rights 03/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac Earnings Call Transcript: H2 2025
2025 saw 7.9% organic growth, strong margin discipline, and record R&D and CapEx investment, with all regions and segments contributing. 2026 guidance targets 5.5%-7.5% revenue growth, 17% EBITDA margin, and continued expansion in pet food and innovation platforms.
Virbac Earnings release: H2 2025
Virbac released its H2 2025 earnings on March 18, 2026, summarizing the period's financial results.
Virbac Slides: H2 2025
Virbac has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 18, 2026.
Virbac Annual report: H2 2025
Virbac has published its H2 2025 annual report on March 18, 2026.
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
Public release of Virbac Consolidated Accounts at 31 December 2025. The Group released its 2025 Consolidated Accounts.
Virbac: 2025 annual results
A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9% Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and coun...
Virbac : Declaration of the number of shares and voting rights 02/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac : Declaration of the number of shares and voting rights 01/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the Fr...
Virbac Earnings release: Q4 2025
Virbac released its Q4 2025 earnings on January 19, 2026, summarizing the period's financial results.
Virbac : Declaration of the number of shares and voting rights 11/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the Fre...
VIRBAC Announces Third Quarter 2025 Sales
Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scope Upgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at cons...
Virbac Earnings release: Q3 2025
Virbac released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.
Virbac Earnings Call Transcript: H1 2025
H1 2025 saw 5.6% organic growth, strong performance in most regions, and robust contributions from new products and acquisitions. EBIT margin declined due to temporary effects, but guidance and long-term targets remain unchanged. CapEx and R&D investments are accelerating.